IndiTreat® is an IVD test, and therefore supported by Clinical Evidence
After 14 years of research and development to improve the care for patients with mCRC, the IndiTreat® test is the first CE-IVD marked drug sensitivity test using three-dimensional tumoroids. Tumoroids are derived from fresh samples of metastatic colorectal cancer (CRC) tissue – either from a needle or endoscopic biopsy.
IndiTreat® determines tumoroid growth inhibition by exposing many hundreds of these mini tumors in vitro to approved antineoplastic drugs and provides the treating oncologist with growth inhibition rates for each of the approved medications that come in question according to standard of care.
We will look at the three areas for IndiTreat®.